AMRX Earnings Date: Nov 3, 2026 (Estimated) — Amneal Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is AMRX's next earnings date?
Amneal Pharmaceuticals, Inc. (AMRX) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.24 on revenue of $817.8M.
How did AMRX do in its last earnings report?
In its most recent report on Jul 30, 2026 (Q2 2026), Amneal Pharmaceuticals, Inc. posted EPS of $0.30 versus the $0.23 estimate, a beat of 30.4%. Revenue was $796.2M against a $765.7M estimate. The stock's 1-day post-earnings move was -3.1%.
How much does AMRX stock move after earnings?
AMRX beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.0% (up or down) in the day after earnings.
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | 0.23 | 0.30 | +30.43% | $796.2M | ✅ Beat | -3.14% | -3.35% | -5.71% |
| 2026-05-07 | Q1 2026 | 0.17 | 0.27 | +58.82% | $722.5M | ✅ Beat | -3.79% | -10.86% | -0.07% |
| 2026-02-27 | Q4 2025 | 0.18 | 0.21 | +16.67% | $814.3M | ✅ Beat | -4.69% | -8.49% | -18.22% |
| 2025-10-30 | Q3 2025 | 0.13 | 0.17 | +30.77% | $784.5M | ✅ Beat | -4.12% | +12.08% | +20.04% |
| 2025-08-05 | Q2 2025 | 0.17 | 0.25 | +47.06% | $725.0M | ✅ Beat | +2.14% | +11.06% | +19.85% |
| 2025-02-28 | Q4 2024 | 0.15 | 0.12 | -20.00% | $730.5M | ❌ Miss | +3.46% | +4.53% | -1.19% |
| 2024-11-08 | Q3 2024 | 0.13 | 0.16 | +23.08% | $702.5M | ✅ Beat | +1.39% | +4.53% | -6.04% |
| 2024-08-09 | Q2 2024 | 0.14 | 0.16 | +14.29% | $701.8M | ✅ Beat | -1.54% | +1.80% | +8.88% |
Showing last 8 quarters.